None listed
Conditions
Interventions
Biological/Vaccine, Stem Cell : Perform percutaneous coronary intervention for myocardial infarction patients.
After DARBEPOETIN 300g single intravenous injection and G-CSF subcutaneous injection (2 t
Sponsors
Seoul National University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: [1st Inclusion Criteria] 1) Patients diagnosed with acute myocardial infarction within 4 weeks of age 19 and under 80 [2nd Inclusion Criteria] 2) Patients who received successful percutaneous angioplasty (the criterion for successful angioplasty was defined as the case where the target coronary artery TMI III blood flow and residual lesion stenosis were less than 30%) using DES or DCB for the culprit lesion. (However, DCB are used only when restenosis occurs in lesions target lesion, resulting in myocardial infarction.)
Exclusion criteria
Exclusion criteria: 1) Ongoing end-stage heart failure or symptoms of heart failure (Killip class II or higher or left ventricular ejection rate 2.0mg/dL) 8) Pregnant or lactating patients 9) Patients participating in clinical studies other than the Registry study. However, as long as the validity is not affected, duplicate registration is possible only with the consent of both practitioners.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Myocardiacl SPECT, Left ventricular ejection rate, Wall motion score index measured by echocardiography, 6-minute walking ability test results | — |
Secondary
| Measure | Time frame |
|---|---|
| MACE: death, revascularization of target lesions, readmission | — |
Countries
Korea, Republic of
Contacts
Public Contactyejin lim
Seoul National University Hospital
Outcome results
None listed